Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taletrectinib in advanced solid tumors
NCT02279433Phase 1Completed
- Sponsor
- Nuvation Bio
- Start
- Sep 2014
- Primary completion
- Mar 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taletrectinib in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more, sponsored by Nuvation Bio. Primary endpoints: Dose-Limiting Toxicities at 21 days and Tumor Response at 2 years. Started Sep 2014; status: completed.
02
Drugs
taletrectinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT02279433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279433.